SCHEDULE: Van Herk Investments Petitions Dutch Court Against ProQR

Van Herk Investments and other shareholders have filed a petition with the Dutch Enterprise Chamber seeking an investigation into ProQR Therapeutics' corporate governance and requesting the appointment of an independent director.

Summary

• Van Herk Investments B.V. (VHI et al.) has filed a petition with the Enterprise Chamber of the Amsterdam Court of Appeal against ProQR Therapeutics N.V.
• The petition requests an investigation into ProQR's policies and conduct of affairs, citing systematic deviations from its own governance rules and applicable standards.
• Specifically, VHI et al. allege issues with director reappointments, board composition, independence, director compensation, and overall company performance.
• As an immediate relief measure, VHI et al. are requesting the appointment of an independent non-executive director to the ProQR board.
• The petitioners claim that ProQR's board has failed to take corrective measures despite repeated objections from long-term shareholders.
• Concerns include alleged violations of the Dutch Corporate Governance Code and ProQR's own Board Rules regarding director tenure, particularly concerning James Shannon.
• The petition also highlights disappointing financial performance and delays in RNA technology development compared to competitors.
• VHI et al. hold approximately 10.9% of ProQR's shares and have been shareholders since 2023.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative, reflecting a significant shareholder dispute and formal legal action alleging serious corporate governance failures and underperformance.

Positives

• ProQR Therapeutics has a collaboration with Eli Lilly and Company, a major pharmaceutical firm.
• The company is developing RNA therapies for rare and common diseases.
• ProQR received approval to begin clinical trials for its Axiomer RNA-editing platform in October 2025.
• Initial research data on target binding for AX-0810 was announced on June 25, 2026.
• ProQR has a substantial cash position, expected to fund operations into mid-2027.
• The company announced a capital issuance of approximately USD 50 million on June 25, 2026, including a private placement to Eli Lilly.

Negatives

• Allegations of systematic deviations from ProQR's own governance rules and applicable governance standards by the board.
• Concerns regarding the reappointment of directors, specifically James Shannon, exceeding maximum cumulative term limits.
• Lack of transparency and justification for director compensation, including substantial bonuses and stock options despite poor company performance.
• ProQR's performance has lagged behind competitors in RNA technology development, with delays in clinical trial progress.
• The collaboration with Eli Lilly has not progressed as expected, with one program being returned and future milestone payments canceled.
• No new business development partnerships have been established.
• The company has incurred significant net losses annually since its founding.
• The share price has experienced a substantial decline, reflecting market concerns.

Risks

• Systematic deviations from ProQR's own governance rules and applicable governance standards.
• Potential for groupthink and lack of independent oversight due to long-serving board members and intertwined networks.
• Risk of continued underperformance relative to competitors in RNA technology development.
• Stagnation of the collaboration with Eli Lilly and potential termination or scaling back.
• Failure to attract new business development partnerships.
• Delays in RNA technology development and research, impacting the path to clinical efficacy data.
• Financial risks associated with high cash burn and limited revenue prospects in the short term.
• Potential for further shareholder value destruction if governance issues are not addressed.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from ProQR Therapeutics. However, the petition by VHI et al. implies concerns about the company's future performance and governance, suggesting a need for corrective actions to ensure long-term value creation and avoid negative consequences.

Management Comments

• ProQR's Board believes retaining the experience of directors like Daniel de Boer and James Shannon is in the company's best interest.
• ProQR asserts that its Board has demonstrated self-criticism and proactivity by adjusting its strategy and board composition in response to market conditions.
• ProQR states that the Board regularly evaluates its performance and composition and makes changes where necessary.
• ProQR disputes the commitment made on May 6, 2024, regarding James Shannon's reappointment.
• ProQR claims that executive compensation is in line with policy and that less than 50% of target long-term incentive bonuses have been awarded over the past five years.
• ProQR's Board intends to exercise its powers regarding the capital structure exclusively in the interest of ProQR's mission and its stakeholders.

Industry Context

StockSavvy.ai notes that this filing highlights significant governance concerns within the biotechnology sector, where investor activism can be pronounced due to the high-risk, high-reward nature of drug development and the critical importance of effective board oversight. The dispute centers on adherence to corporate governance standards, which are crucial for maintaining investor confidence and ensuring long-term strategic execution in a competitive landscape.

Comparison to Industry Standards

• The petition alleges that ProQR's board composition and director tenure violate the Dutch Corporate Governance Code and ProQR's own Board Rules, which are designed to prevent groupthink and ensure independent oversight, standards common in well-governed public companies globally.
• Competitors like Wave Life Sciences Ltd. and Korro Bio Inc. are mentioned as having made faster progress toward clinical validation, suggesting ProQR lags behind industry benchmarks in development timelines.
• The petition cites an Accuracy Report indicating ProQR's board has a relatively high degree of interdependence through external organizations, which is contrary to industry best practices emphasizing board independence.
• ProQR's compensation practices, particularly large option grants to executives despite poor performance, are contrasted with industry norms where compensation is typically more closely tied to demonstrable value creation and shareholder returns.
• The petition criticizes ProQR's deviation from best practice provision 3.2.3 of the Dutch Corporate Governance Code regarding severance pay caps, which is a common regulatory consideration across major markets.

Corporate Governance

Legal Proceedings

• Petition for Inquiry filed with the Enterprise Chamber of the Amsterdam Court of Appeal by Van Herk Investments B.V. and other related entities against ProQR Therapeutics N.V.
• The petition requests an investigation into ProQR's policies and conduct of affairs and seeks immediate relief measures, including the appointment of an independent non-executive director.

Related Party Transactions

• The petition highlights concerns about the composition and functioning of the Compensation, Nominating, and Corporate Governance (CNC) Committee, noting that its chairperson (Heggie) was previously an employee and that James Shannon, a director with an extended tenure, is a member.
• The capital issuance on June 25, 2026, involved a private placement to Eli Lilly, a key partner, while VHI et al. were not given the same opportunity to participate as in previous capital increases, raising concerns about unequal treatment.

Stakeholder Impact

• Shareholders are directly impacted by the allegations of governance failures, disappointing performance, and potential value destruction, leading to a shareholder dispute and legal action.
• The petition suggests that the board's actions may not be in the best interests of all stakeholders, including shareholders, due to alleged self-serving decisions and lack of accountability.
• Employees could be indirectly impacted by potential instability or changes resulting from the governance dispute and legal proceedings.
• Partners, such as Eli Lilly, may be affected by the ongoing governance issues and the company's strategic direction.

Next Steps

• The Enterprise Chamber of the Amsterdam Court of Appeal will review the petition for an investigation and the request for immediate relief measures.
• ProQR Therapeutics will likely respond to the allegations and the court's proceedings.
• The outcome of the court's decision will determine if an investigation is ordered and if an independent director is appointed.

Key Dates

Recommendation

The filing indicates significant governance concerns and a shareholder dispute, which introduces substantial uncertainty and risk. While the company is in the biotechnology sector with potential upside, the current legal action and allegations of mismanagement warrant a cautious approach. Investors should monitor the outcome of the legal proceedings and ProQR's response to governance criticisms before considering any significant investment action.

Keywords

corporate governance, shareholder dispute, board of directors, investigation petition, RNA therapies, biotechnology, regulatory filing, Amsterdam Court of Appeal